Literature DB >> 29868924

The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.

Dane H Dougherty1, Linda Kwakkenbos2,3,4, Marie-Eve Carrier3, Gloria Salazar1, Shervin Assassi1, Murray Baron3,5, Susan J Bartlett5,6,7, Daniel E Furst8,9,10, Karen Gottesman11, Frank van den Hoogen12,13, Vanessa L Malcarne14,15, Luc Mouthon16,17, Warren R Nielson18,19, Serge Poiraudeau16,20,21, Maureen Sauvé22,23, Gilles Boire24, Alessandra Bruns24, Lorinda Chung25, Christopher Denton26, James V Dunne27,28, Paul Fortin29, Tracy Frech30, Anna Gill27, Jessica Gordon31, Ariane L Herrick32, Monique Hinchcliff33, Marie Hudson5,34, Sindhu R Johnson35,36, Niall Jones37, Suzanne Kafaja8, Maggie Larché38, Joanne Manning39, Janet Pope40, Robert Spiera31, Virginia Steen41, Evelyn Sutton42, Carter Thorne43, Pearce Wilcox28,29, Brett D Thombs2,3,5,44,45,46,47, Maureen D Mayes1.   

Abstract

Objectives: The Scleroderma Patient-centered Intervention Network (SPIN) Cohort is a web-based cohort designed to collect patient-reported outcomes at regular intervals as a framework for conducting trials of psychosocial, educational, self-management and rehabilitation interventions for patients with SSc. The aim of this study was to present baseline demographic, medical and patient-reported outcome data of the SPIN Cohort and to compare it with other large SSc cohorts.
Methods: Descriptive statistics were used to summarize SPIN Cohort characteristics; these were compared with published data of the European Scleroderma Trials and Research (EUSTAR) and Canadian Scleroderma Research Group (CSRG) cohorts.
Results: Demographic, organ involvement and antibody profile data for SPIN (N = 1125) were generally comparable with that of the EUSTAR (N = 7319) and CSRG (N = 1390) cohorts. There was a high proportion of women and White patients in all cohorts, though relative proportions differed. Scl70 antibody frequency was highest in EUSTAR, somewhat lower in SPIN, and lowest in CSRG, consistent with the higher proportion of interstitial lung disease among dcSSc patients in SPIN compared with in CSRG (48.5 vs 40.3%). RNA polymerase III antibody frequency was highest in SPIN and remarkably lower in EUSTAR (21.1 vs 2.4%), in line with the higher prevalence of SSc renal crisis (4.5 vs 2.1%) in SPIN.
Conclusion: Although there are some differences, the SPIN Cohort is broadly comparable with other large prevalent SSc cohorts, increasing confidence that insights gained from the SPIN Cohort should be generalizable, although it should be noted that all three cohorts include primarily White participants.

Entities:  

Mesh:

Year:  2018        PMID: 29868924     DOI: 10.1093/rheumatology/key139

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  14 in total

1.  Cultural adaptation, translation and validation of Cochin Hand Function Scale and evaluation of hand dysfunction in systemic sclerosis.

Authors:  Devender Bairwa; Chengappa G Kavadichanda; M B Adarsh; Aishwarya Gopal; Vir Singh Negi
Journal:  Clin Rheumatol       Date:  2020-10-15       Impact factor: 2.980

2.  The Scleroderma Research Topics Survey for patients and health care professionals: A Scleroderma Patient-centered Intervention Network Project.

Authors:  Lydia Tao; Claire Fedoruk; Kimberly A Turner; Julie Cumin; Marie-Eve Carrier; Andrea Carboni-Jiménez; Mia R Pépin; Linda Kwakkenbos; Brett D Thombs
Journal:  J Scleroderma Relat Disord       Date:  2019-04-23

3.  Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients.

Authors:  Brett D Thombs; Linda Kwakkenbos; Marie-Eve Carrier; Angelica Bourgeault; Lydia Tao; Sami Harb; Maria Gagarine; Danielle Rice; Laura Bustamante; Kelsey Ellis; Delaney Duchek; Yin Wu; Parash Mani Bhandari; Dipika Neupane; Andrea Carboni-Jiménez; Richard S Henry; Ankur Krishnan; Ying Sun; Brooke Levis; Chen He; Kimberly A Turner; Andrea Benedetti; Nicole Culos-Reed; Ghassan El-Baalbaki; Shannon Hebblethwaite; Susan J Bartlett; Laura Dyas; Scott Patten; John Varga
Journal:  J Psychosom Res       Date:  2020-05-14       Impact factor: 3.006

4.  Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study.

Authors:  Yin Wu; Linda Kwakkenbos; Richard S Henry; Marie-Eve Carrier; Maria Gagarine; Sami Harb; Angelica Bourgeault; Lydia Tao; Andrea Carboni-Jiménez; Zelalem Negeri; Scott Patten; Susan J Bartlett; Luc Mouthon; John Varga; Andrea Benedetti; Brett D Thombs
Journal:  J Psychosom Res       Date:  2020-11-25       Impact factor: 3.006

5.  Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study.

Authors:  Brett D Thombs; Linda Kwakkenbos; Richard S Henry; Marie-Eve Carrier; Scott Patten; Sami Harb; Angelica Bourgeault; Lydia Tao; Susan J Bartlett; Luc Mouthon; John Varga; Andrea Benedetti
Journal:  J Psychosom Res       Date:  2020-10-03       Impact factor: 3.006

6.  Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial.

Authors:  Brett D Thombs; Linda Kwakkenbos; Brooke Levis; Angelica Bourgeault; Richard S Henry; Alexander W Levis; Sami Harb; Lydia Tao; Marie-Eve Carrier; Laura Bustamante; Delaney Duchek; Laura Dyas; Ghassan El-Baalbaki; Kelsey Ellis; Danielle B Rice; Amanda Wurz; Julia Nordlund; Maria Gagarine; Kimberly A Turner; Nora Østbø; Nicole Culos-Reed; Shannon Hebblethwaite; Scott Patten; Susan J Bartlett; John Varga; Luc Mouthon; Sarah Markham; Michael S Martin; Andrea Benedetti
Journal:  Lancet Rheumatol       Date:  2021-04-16

7.  Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study.

Authors:  Jessica K Gordon; Kimberly Showalter; Yin Wu; Linda Kwakkenbos; Marie-Eve Carrier; Richard S Henry; Nora Østbø; Julia Nordlund; Angelica Bourgeault; Mara Cañedo-Ayala; Andrea Carboni-Jiménez; Christopher P Denton; Luc Mouthon; Brett D Thombs; Robert F Spiera
Journal:  Lancet Rheumatol       Date:  2022-01-18

Review 8.  Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.

Authors:  Dinesh Khanna; Alain Lescoat; David Roofeh; Elana J Bernstein; Ella A Kazerooni; Michael D Roth; Fernando Martinez; Kevin R Flaherty; Christopher P Denton
Journal:  Arthritis Rheumatol       Date:  2021-11-10       Impact factor: 15.483

9.  Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma atient-centred Intervention Network (SPIN) Cohort Study.

Authors:  Sophia J Sommer; Daphna Harel; Linda Kwakkenbos; Marie-Eve Carrier; Shadi Gholizadeh; Karen Gottesman; Catarina Leite; Vanessa L Malcarne; Brett D Thombs
Journal:  BMJ Open       Date:  2020-10-12       Impact factor: 2.692

10.  Pain and Self-Efficacy Among Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study.

Authors:  Robyn K Wojeck; Susan G Silva; Donald E Bailey; Mitchell R Knisely; Linda Kwakkenbos; Marie-Eve Carrier; Warren R Nielson; Susan J Bartlett; Janet Pope; Brett D Thombs
Journal:  Nurs Res       Date:  2021 Set/Oct 01       Impact factor: 2.381

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.